Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.

Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.

Cancer Immunol Res. 2019 Oct;7(10):1633-1646. doi: 10.1158/2326-6066.CIR-18-0579. Epub 2019 Aug 20.

PMID:
31431433
2.

Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.

Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D.

Sci Adv. 2019 Feb 20;5(2):eaav2437. doi: 10.1126/sciadv.aav2437. eCollection 2019 Feb.

3.

Role of FcγRs in Antibody-Based Cancer Therapy.

Graziano RF, Engelhardt JJ.

Curr Top Microbiol Immunol. 2019;423:13-34. doi: 10.1007/82_2019_150. Review.

PMID:
30790079
4.

Characterization of Mauritian Cynomolgus Macaque FcγR Alleles Using Long-Read Sequencing.

Haj AK, Arbanas JM, Yamniuk AP, Karl JA, Bussan HE, Drinkwater KY, Graham ME, Ericsen AJ, Prall TM, Moore K, Cheng L, Gao M, Graziano RF, Loffredo JT, Wiseman RW, O'Connor DH.

J Immunol. 2019 Jan 1;202(1):151-159. doi: 10.4049/jimmunol.1800843. Epub 2018 Dec 10.

5.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, Jenkins MR, Rogers AJ, Neeson PJ, Korman AJ, Robbins MD, Graziano RF.

Blood Adv. 2017 May 8;1(12):753-765. doi: 10.1182/bloodadvances.2017004382. eCollection 2017 May 9.

6.

Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A Interaction.

Huang RY, Krystek SR Jr, Felix N, Graziano RF, Srinivasan M, Pashine A, Chen G.

MAbs. 2018 Jan;10(1):95-103. doi: 10.1080/19420862.2017.1393595. Epub 2017 Nov 14.

7.

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Pazina T, James AM, MacFarlane AW 4th, Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD, Campbell KS.

Oncoimmunology. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853. eCollection 2017.

8.

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.

Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD.

Cancer Immunol Res. 2017 Feb;5(2):106-117. doi: 10.1158/2326-6066.CIR-16-0391. Epub 2017 Jan 10.

9.

In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.

Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Passmore D, Chen TH, Chen S, Liu J, Kuhne MR, Srinivasan M, Assad A, Witte A, Graziano RF, King DJ.

Clin Cancer Res. 2009 May 15;15(10):3376-83. doi: 10.1158/1078-0432.CCR-08-3222. Epub 2009 Apr 28.

10.

Readers' responses to "is national health insurance coming to the United States?".

Graziano RF.

MedGenMed. 2006;8(3):81; author reply 78. No abstract available.

PMID:
17410688
11.

Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.

Bevaart L, Goldstein J, Vitale L, Russoniello C, Treml J, Zhang J, Graziano RF, Leusen JH, van de Winkel JG, Keler T.

Br J Haematol. 2006 Feb;132(3):317-25.

PMID:
16409296
12.
13.

Development of antibody-targeted vaccines.

Keler T, He L, Graziano RF.

Curr Opin Mol Ther. 2005 Apr;7(2):157-63. Review.

PMID:
15844624
14.

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.

Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM.

J Infect Dis. 2005 Feb 15;191(4):507-14. Epub 2005 Jan 14.

PMID:
15655773
15.

Chemical production of bispecific antibodies.

Graziano RF, Guptill P.

Methods Mol Biol. 2004;283:71-85.

PMID:
15197303
16.

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.

Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, Lonberg N, Korman A.

J Immunol. 2003 Dec 1;171(11):6251-9.

17.

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.

Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A.

Blood. 2003 Nov 15;102(10):3737-42. Epub 2003 Jul 24.

PMID:
12881320
18.
19.

Receptor modulation by Fc gamma RI-specific fusion proteins is dependent on receptor number and modified by IgG.

Guyre CA, Keler T, Swink SL, Vitale LA, Graziano RF, Fanger MW.

J Immunol. 2001 Dec 1;167(11):6303-11.

20.

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.

Sundarapandiyan K, Keler T, Behnke D, Engert A, Barth S, Matthey B, Deo YM, Graziano RF.

J Immunol Methods. 2001 Feb 1;248(1-2):113-23.

PMID:
11223073
21.

Uptake of antigen-antibody complexes by human dendritic cells.

Fanger NA, Guyre PM, Graziano RF.

Methods Mol Med. 2001;64:377-86. doi: 10.1385/1-59259-150-7:377.

PMID:
21374276
22.

Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.

Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van De Winkel JG, Deo YM, Graziano RF.

J Immunol. 2000 Dec 15;165(12):6738-42.

23.

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T.

J Immunol. 2000 Nov 15;165(10):5954-61.

24.

Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages.

Keler T, Wallace PK, Vitale LA, Russoniello C, Sundarapandiyan K, Graziano RF, Deo YM.

J Immunol. 2000 Jun 1;164(11):5746-52.

25.

Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.

Somasundaram C, Sundarapandiyan K, Keler T, Deo YM, Graziano RF.

Hum Antibodies. 1999;9(1):47-54.

PMID:
10331185
27.

Increased potency of Fc-receptor-targeted antigens.

Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli PM, Wardwell K, Howell AL.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):146-8. Review.

PMID:
9435859
28.

Targeting tumor cell destruction with CD64-directed bispecific fusion proteins.

Graziano RF, Goldstein J, Sundarapandiyan K, Somasundaram C, Keler T, Deo YM.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):124-7. No abstract available.

PMID:
9435854
29.

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG.

Blood. 1997 Dec 1;90(11):4485-92.

PMID:
9373259
30.

Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.

Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW, Deo YM.

Cancer Res. 1997 Sep 15;57(18):4008-14.

31.

Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcgammaRI), blocks phagocytosis, and modulates receptor expression.

Wallace PK, Keler T, Coleman K, Fisher J, Vitale L, Graziano RF, Guyre PM, Fanger MW.

J Leukoc Biol. 1997 Oct;62(4):469-79.

PMID:
9335317
32.

Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells.

Fanger NA, Voigtlaender D, Liu C, Swink S, Wardwell K, Fisher J, Graziano RF, Pfefferkorn LC, Guyre PM.

J Immunol. 1997 Apr 1;158(7):3090-8.

PMID:
9120261
33.

Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies.

Deo YM, Graziano RF, Repp R, van de Winkel JG.

Immunol Today. 1997 Mar;18(3):127-35. Review.

PMID:
9078685
34.

Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.

Goldstein J, Graziano RF, Sundarapandiyan K, Somasundaram C, Deo YM.

J Immunol. 1997 Jan 15;158(2):872-9.

PMID:
8993006
35.

F(c)gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes.

Liu C, Goldstein J, Graziano RF, He J, O'Shea JK, Deo Y, Guyre PM.

J Clin Invest. 1996 Nov 1;98(9):2001-7.

36.

Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma.

Ely P, Wallace PK, Givan AL, Graziano RF, Guyre PM, Fanger MW.

Blood. 1996 May 1;87(9):3813-21.

PMID:
8611707
37.

Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice.

Heijnen IA, van Vugt MJ, Fanger NA, Graziano RF, de Wit TP, Hofhuis FM, Guyre PM, Capel PJ, Verbeek JS, van de Winkel JG.

J Clin Invest. 1996 Jan 15;97(2):331-8.

38.

Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody.

Graziano RF, Tempest PR, White P, Keler T, Deo Y, Ghebremariam H, Coleman K, Pfefferkorn LC, Fanger MW, Guyre PM.

J Immunol. 1995 Nov 15;155(10):4996-5002.

PMID:
7594506
39.

Production and use of anti-FcR bispecific antibodies.

Fanger MW, Graziano RF, Guyre PM.

Immunomethods. 1994 Feb;4(1):72-81. Review.

PMID:
8069530
41.
42.

Human alveolar macrophage FcR-mediated cytotoxicity. Heteroantibody- versus conventional antibody-mediated target cell lysis.

Levy PC, Looney RJ, Shen L, Graziano RF, Fanger MW, Roberts NJ Jr, Ryan DH, Utell MJ.

J Immunol. 1990 May 15;144(10):3693-700.

PMID:
2332629
43.

The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells.

Erbe DV, Collins JE, Shen L, Graziano RF, Fanger MW.

Mol Immunol. 1990 Jan;27(1):57-67.

PMID:
2138246
44.
46.

Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function.

Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW.

J Immunol. 1989 Sep 1;143(5):1650-5.

PMID:
2474608
47.

Cytotoxicity mediated by human Fc receptors for IgG.

Fanger MW, Shen L, Graziano RF, Guyre PM.

Immunol Today. 1989 Mar;10(3):92-9. Review.

PMID:
2525910
48.

Fc gamma R in cytotoxicity exerted by mononuclear cells.

Fanger MW, Graziano RF, Shen L, Guyre PM.

Chem Immunol. 1989;47:214-53. Review. No abstract available.

PMID:
2532893
49.

Fc gamma R-mediated killing by eosinophils.

Graziano RF, Looney RJ, Shen L, Fanger MW.

J Immunol. 1989 Jan 1;142(1):230-5.

PMID:
2521234
50.

Supplemental Content

Loading ...
Support Center